Top
image credit: Pixabay

Pfizer buys a private biotech and its RSV drug research

April 7, 2022

Category:

RSV is one of the most common, and confounding, viruses that cause infections in humans. There’s no approved vaccine and current treatment options focus on managing symptoms, much like a cold.

For most people who contract RSV, that’s enough; they generally suffer only cold-like symptoms. But the virus can be deadly for infants or the elderly. RSV leads to 58,000 hospitalizations of children younger than 5 every year in the U.S. and 177,000 hospitalizations among those 65 and older, according to the Centers for Disease Control and Prevention. The virus kills some 14,000 elderly Americans annually.

Read More on Biopharma Dive